68
Participants
Start Date
November 17, 2020
Primary Completion Date
July 31, 2024
Study Completion Date
November 30, 2024
Lorlatinib
Lorlatinib is administered orally at the daily dose of 100 mg (four tablets of 25 mg).
Institut Jules Bordet-Hopital Universitaire ULB, Brussels
CHU-UCL Namur - CHU Mont Godinne - UCL Namur, Yvoir
Hospital General Universitario Gregorio Maranon, Madrid
CHU de Brest, Brest
Centre Hospitalier Avignon, Avignon
Centre Hopitalier Intercommunal De Creteil, Créteil
Cliniques Universitaires Saint-Luc, Brussels
Universitair Ziekenhuis Antwerpen, Edegem
Assistance Publique Hopitaux Paris - Hopital Avicenne, Bobigny
Gustave Roussy, Villejuif
King Hussein Cancer Center, Amman
Academisch Ziekenhuis Maastricht, Maastricht
Erasmus MC, Rotterdam
Oslo University Hospital - Radiumhospitalet, Oslo
Hospital Clinic Universitari de Barcelona, Barcelona
Hospital De La Santa Creu I Sant Pau, Barcelona
Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol, Barcelona
Clinica Universidad de Navarra - Clinica Universitaria De Navarra, Madrid
Hospital Universitario 12 De Octubre, Madrid
Hospital Universitario Ramon y Cajal, Madrid
Hospital Universitari Son Espases, Palma de Mallorca
Clinica Universidad de Navarra - Clinica Universitaria De Navarra, Pamplona
University Hospital Virgen del Rocio, Seville
The Christie NHS Foundation Trust, Manchester
The Netherlands Cancer Institute-Antoni Van Leeuwenhoekziekenhuis, Amsterdam
Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals, L'Hospitalet de Llobregat
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK